|
Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. |
| |
|
Consulting or Advisory Role - Abbvie; Actelion; Blue Earth Diagnostics; Bristol-Myers Squibb; Cavion; Celldex; MSD; Novartis; Roche |
Research Funding - Abbvie (Inst) |
| |
|
|
Consulting or Advisory Role - Roche |
| |
|
Consulting or Advisory Role - Abbvie (Inst); PAREXEL (Inst) |
| |
|
Travel, Accommodations, Expenses - Roche |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Air Liquide; CarThera |
Travel, Accommodations, Expenses - Roche |
| |
|
No Relationships to Disclose |
| |
Filip Yves Francine Leon De Vos |
Consulting or Advisory Role - Bristol-Myers Squibb (Inst) |
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
| |
|
Honoraria - MSD Oncology; Prime Oncology; Roche/Genentech |
Consulting or Advisory Role - Celldex; Roche/Genentech |
Research Funding - Apogenix (Inst); Boehringer Ingelheim (Inst); Roche (Inst) |
| |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Abbvie (Inst) |